Lexicon Pharmaceuticals (NASDAQ:LXRX) Given Outperform Ratin

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Leerink Partnrs in a report issued on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 […]

Related Keywords

Switzerland , Swiss , Leerink Partnrs , Needham Company , Commonwealth Equity Services , Nasdaq , Lexicon Pharmaceuticals Trading , Lexicon Pharmaceuticals , Lexicon Pharmaceuticals Inc , News Ratings For Lexicon Pharmaceuticals Daily , Sg Americas Securities , Swiss National Bank , National Association , Get Free Report , Equity Services , National Bank , Lexicon Pharmaceuticals Daily , Nasdaq Lxrx , Lxrx , Medical , 52887210 , Reiterated Rating ,